Biotage Receives its Largest Order to Date
News Aug 12, 2005
Biotage has announced that it has received its largest single order to date. It includes 31 instruments and totals approx. 15 MSEK.
The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.
The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.
"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.
He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."
The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE